Companies › Telios Pharma
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TL-925 | – | Phase 2 | Allergic Conjunctivitis | – |
| TL-895 Irreversible tyrosine kinase inhibitor | – | Phase 1 | Myelofibrosis | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06686472 | TL-925 | Phase 2 | Allergic Conjunctivitis | Immunology | Dec 2024 |
| NCT07220408 | TL-925 | Phase 2 | Allergic Conjunctivitis | Immunology | Feb 2026 |
| NCT05280509 | TL-895 | Phase 1 | Myelofibrosis | Oncology | Apr 2027 |
No annotated target.
–
Molecure Tavotek Biotherapeutics Xizang Haisco Pharmaceutical Antengene Biologics Ganzhou Hemay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.